AZD 7624
Alternative Names: AZD-7624Latest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Class Antiasthmatics; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 30 Sep 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
- 30 Sep 2016 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Netherlands, Argentina, Chile, Peru, South Africa, USA (Inhalation) because of unfavourable safety and efficacy results (AstraZeneca pipeline, November 2016; AstraZeneca quarterly report, November 2016)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (Inhalation, Aerosol)